Biopharma Investment in China is Thriving Amid U.S. Downturn

Despite the economic slowdown, driven in no small part by stringent pandemic measures and growing geopolitical tensions, China remains one of the world’s top business hubs. Many healthcare, pharmaceutical and biotech companies continue to place their bets on the East Asian giant, bringing fresh rounds of investments to and forging new partnerships with local firms. Read on for more analyses and announcements.